Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR4 versus insulin glargine U100 in type 2 diabetes
NCT06767761Phase 3Active, not recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of GZR4 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Hemoglobin A1c at 26 weeks. Started Feb 2025; status: active, not recruiting.
02
Drugs
GZR4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06767761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06767761.